Goldman Sachs Group Inc Biogen Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Biogen Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 989,041 shares of BIIB stock, worth $145 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
989,041
Previous 1,420,860 30.39%
Holding current value
$145 Million
Previous $329 Million 41.8%
% of portfolio
0.03%
Previous 0.06%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$189.07 - $236.8 $81.6 Million - $102 Million
-431,819 Reduced 30.39%
989,041 $192 Million
Q2 2024

Aug 13, 2024
BUY
$190.52 - $236.72 $81.3 Million - $101 Million
426,495 Added 42.89%
1,420,860 $329 Million
Q1 2024

May 15, 2024
SELL
$212.02 - $267.71 $21.5 Million - $27.2 Million
-101,458 Reduced 9.26%
994,365 $214 Million
Q4 2023

Feb 13, 2024
BUY
$222.59 - $267.94 $67.9 Million - $81.7 Million
304,978 Added 38.56%
1,095,823 $284 Million
Q3 2023

May 14, 2024
SELL
$253.3 - $285.89 $77.3 Million - $87.2 Million
-304,978 Reduced 27.83%
790,845 $203 Million
Q3 2023

Nov 14, 2023
SELL
$253.3 - $285.89 $8.82 Million - $9.95 Million
-34,820 Reduced 4.22%
790,845 $203 Million
Q2 2023

May 14, 2024
BUY
$275.25 - $318.06 $45.2 Million - $52.2 Million
164,216 Added 24.83%
825,665 $235 Million
Q2 2023

Aug 14, 2023
BUY
$275.25 - $318.06 $45.2 Million - $52.2 Million
164,216 Added 24.83%
825,665 $235 Million
Q1 2023

May 14, 2024
SELL
$256.56 - $292.34 $81.4 Million - $92.8 Million
-317,433 Reduced 32.43%
661,449 $184 Million
Q1 2023

May 11, 2023
SELL
$256.56 - $292.34 $81.4 Million - $92.8 Million
-317,433 Reduced 32.43%
661,449 $184 Million
Q4 2022

May 14, 2024
SELL
$252.44 - $306.72 $106 Million - $128 Million
-418,762 Reduced 29.96%
978,882 $271 Million
Q4 2022

Feb 13, 2023
SELL
$252.44 - $306.72 $106 Million - $128 Million
-418,762 Reduced 29.96%
978,882 $271 Million
Q3 2022

May 14, 2024
SELL
$194.69 - $268.46 $48 Million - $66.1 Million
-246,405 Reduced 14.99%
1,397,644 $373 Million
Q3 2022

Nov 10, 2022
SELL
$194.69 - $268.46 $48 Million - $66.1 Million
-246,405 Reduced 14.99%
1,397,644 $373 Million
Q2 2022

May 14, 2024
BUY
$187.54 - $223.02 $103 Million - $122 Million
548,226 Added 50.03%
1,644,049 $335 Million
Q2 2022

Aug 15, 2022
BUY
$187.54 - $223.02 $62.6 Million - $74.5 Million
333,945 Added 25.49%
1,644,049 $335 Million
Q1 2022

May 16, 2022
BUY
$193.77 - $244.14 $69.9 Million - $88.1 Million
360,864 Added 38.02%
1,310,104 $276 Million
Q4 2021

Feb 14, 2022
BUY
$223.92 - $287.77 $33.4 Million - $43 Million
149,312 Added 18.67%
949,240 $228 Million
Q3 2021

Nov 10, 2021
BUY
$282.99 - $369.05 $226 Million - $295 Million
799,928 New
799,928 $226 Million

Others Institutions Holding BIIB

# of Institutions
1,037
Shares Held
126M
Call Options Held
1.13M
Put Options Held
1.43M
View Full List

About BIOGEN INC.

BIIB Quotes by TradingView
  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email